Immucell (ICCC) Price to Earnings (2010 - 2026)

Immucell (ICCC) has reported Price to Earnings for 17 consecutive years, with 49.75 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Price to Earnings fell 60.34% year-over-year to 49.75; the trailing twelve-month figure through Jun 2026 stood at 214.86 (down 858.51% YoY), and the FY2025 full-year result was 68.47, down 151.1% from the prior year.
• Price to Earnings improved to 49.75 in Q2 2026 per ICCC's latest filing, from 21.22 in the prior quarter.
• Across five years, Price to Earnings topped out at 515.78 in Q4 2023 and bottomed at 404.56 in Q3 2025.
• Historically, Price to Earnings has averaged 0.59 across 5 years, with a median of 24.8 in 2024.
• The sharpest annual moves came in 2023 and 2025: Price to Earnings soared 1342.2% in 2023, then tumbled 785.34% in 2025.
• Over 5 years, Price to Earnings stood at 41.52 in 2022, then jumped by 1342.2% to 515.78 in 2023, then plunged by 90.81% to 47.41 in 2024, then tumbled by 144.76% to 21.22 in 2025, then jumped by 334.45% to 49.75 in 2026.
• According to Business Quant data, Price to Earnings over the past three periods registered 49.75, 21.22, and 404.56 for Q2 2026, Q4 2025, and Q3 2025 respectively.